Folks posting on stock twits that irwd has been downgraded due to tolerability issues
This further supports plecanatide as best in class with superior tolerability in patients with CIC and IBS-C. While forest and irwd spend millions building the market, plecanatide will ultimately own the space.
Plecanatide will have majority market share within 24 months of launch
This further supports plecanatide as best in class with superior tolerability in patients with CIC and IBS-C. While forest and irwd spend millions building the market, plecanatide will ultimately own the space.
Plecanatide will have majority market share within 24 months of launch
More downgrades for IRWD
Aucun commentaire:
Enregistrer un commentaire